» Articles » PMID: 33479603

Broad-spectrum Antitumor Properties of Withaferin A: a Proteomic Perspective

Overview
Journal RSC Med Chem
Specialty Chemistry
Date 2021 Jan 22
PMID 33479603
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The multifunctional antitumor properties of Withaferin A (WA), the manifold studied bioactive compound of the plant , have been well established in many different and cancer models. This undoubtedly has led to a much better insight in the underlying mechanisms of WAs broad antitumor activity range, but also raises additional challenging questions on how all these antitumor properties could be explained on a molecular level. Therefore, a lot of effort was made to characterize the cellular WA target proteins, since these binding events will lead and initiate the observed downstream effects. Based on a proteomic perspective, this review provides novel insights in the molecular chain of events by which WA potentially exercises its antitumor activities. We illustrate that WA triggers multiple cellular stress pathways such as the NRF2-mediated oxidative stress response, the heat shock response and protein translation events and at the same time inhibits these cellular protection mechanisms, driving stressed cancer cells towards a fatal state of collapse. If cancer cells manage to restore homeostasis and survive, a stress-independent WA antitumor response comes into play. These include the known inhibition of cytoskeleton proteins, NFκB pathway inhibition and cell cycle inhibition, among others. This review therefore provides a comprehensive overview which integrates the numerous WA-protein binding partners to formulate a general WA antitumor mechanism.

Citing Articles

Chemoproteomics reveals proteome-wide covalent and non-covalent targets of withaferin A.

Nie H, Fu Y, Long S, Wang J, Zhao W, Zhai L Acta Pharmacol Sin. 2025; .

PMID: 39900821 DOI: 10.1038/s41401-024-01468-5.


Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis.

Zhou X, Wu D, Zhu L, Li R, Yu H, Li W Curr Cancer Drug Targets. 2024; 24(5):534-545.

PMID: 38804345 DOI: 10.2174/0115680096262915231026050602.


Withaferin A and Celastrol Overwhelm Proteostasis.

Vilaboa N, Voellmy R Int J Mol Sci. 2024; 25(1).

PMID: 38203539 PMC: 10779417. DOI: 10.3390/ijms25010367.


Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant (L.) Dunal.

Kumar S, Mathew S, Aharwal R, Tulli H, Mohan C, Sethi G Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259311 PMC: 9966696. DOI: 10.3390/ph16020160.


Disruption of Proteostasis by Natural Products and Synthetic Compounds That Induce Pervasive Unfolding of Proteins: Therapeutic Implications.

Vilaboa N, Lopez J, de Mesa M, Escudero-Duch C, Winfield N, Bayford M Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111374 PMC: 10145903. DOI: 10.3390/ph16040616.


References
1.
Shahbazian D, Parsyan A, Petroulakis E, Hershey J, Sonenberg N . eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle. 2010; 9(20):4106-9. PMC: 3055195. DOI: 10.4161/cc.9.20.13630. View

2.
Zhang D, Hannink M . Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23(22):8137-51. PMC: 262403. DOI: 10.1128/MCB.23.22.8137-8151.2003. View

3.
Lee D, Lim I, Sung E, Kim J, Song I, Park Y . Withaferin A inhibits matrix metalloproteinase-9 activity by suppressing the Akt signaling pathway. Oncol Rep. 2013; 30(2):933-8. DOI: 10.3892/or.2013.2487. View

4.
Conour J, Graham W, Gaskins H . A combined in vitro/bioinformatic investigation of redox regulatory mechanisms governing cell cycle progression. Physiol Genomics. 2004; 18(2):196-205. DOI: 10.1152/physiolgenomics.00058.2004. View

5.
Cao S, Kaufman R . Endoplasmic reticulum stress and oxidative stress in cell fate decision and human disease. Antioxid Redox Signal. 2014; 21(3):396-413. PMC: 4076992. DOI: 10.1089/ars.2014.5851. View